Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050)

Diagnostik und Therapie von Frauen mit wiederholten Spontanaborten. Leitlinie der DGGG, OEGGG und SGGG (S2k-Niveau, AWMF-Registernummer 015/050)

Authors
Bettina Toth1, Wolfgang Würfel2, Michael Bohlmann1, Johannes Zschocke4, Sabine Rudnik-Schöneborn4, Frank Nawroth5, Ekkehard Schleußner6, Nina Rogenhofer7, Tewes Wischmann6, Michael von Wolff9, Katharina Hancke10, Sören von Otte11, Ruben Kuon12, Katharina Feil1, Clemens Tempfer13

Affiliations
1 Klinik für Gynäkologische Endokrinologie und Reproduktionsmedizin, Universität Innsbruck, Innsbruck, Austria
2 Kinderwunsch Centrum München, München, Germany
3 Universitätsfrauenklinik Mannheim, Mannheim, Germany
4 Zentrum für Medizinische Genetik, Universität Innsbruck, Innsbruck, Austria
5 Amedes, Hamburg, Germany
6 Klinik für Geburtsmedizin, Uniklinik Jena, Jena, Germany
7 Klinikum der Universität München – Frauenklinik Maistraße, München, Germany
8 Institut für Medizinische Psychologie, Universitätsklinikum Heidelberg, Heidelberg, Germany
9 Universitätsklinik für Frauenheilkunde, Inselspital Bern, Bern, Switzerland
10 Klinik für Frauenheilkunde, Universitätsklinikum Ulm, Ulm, Germany
11 Kinderwunschzentrum, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
12 Universitäts-Frauenklinik Heidelberg, Heidelberg, Germany
13 Universitätsfrauenklinik, Ruhr-Universität Bochum, Bochum, Germany

Key words
recurrent miscarriage, incidence, diagnosis, therapy, recommendations

Schlüsselwörter
wiederholter Spontanabort, Inzidenz, Diagnose, Therapie, Empfehlungen

Bibliography
DOI https://doi.org/10.1055/a-0586-4568
Geburtsh Frauenheilk 2018; 78: 364–381 © Georg Thieme Verlag KG Stuttgart · New York | ISSN 0016‑5751

Correspondence
Prof. Bettina Toth
Klinik für Gynäkologische Endokrinologie und Reproduktionsmedizin, Universität Innsbruck Anichstraße 35, 6020 Innsbruck, Österreich
Bettina.toth@i-med.ac.at

Deutsche Version unter:
https://doi.org/10.1055/a-0586-4568

ABSTRACT

Purpose Official guideline of the German Society of Gynecology and Obstetrics (DGGG), the Austrian Society of Gynecology and Obstetrics (ÖGGG) and the Swiss Society of Gynecology and Obstetrics (SGGG). The aim of this guideline was to standardize the diagnosis and treatment of couples with recurrent miscarriage (RM). Recommendations were based on the current literature and the views of the involved committee members.

Methods Based on the current literature, the committee members developed the statements and recommendations of this guideline in a formalized process which included DELPHI rounds and a formal consensus meeting.

Recommendations Recommendations for the diagnosis and treatment of patients with RM were compiled based on the international literature. Specific established risk factors such as chromosomal, anatomical, endocrine, hemostatic, psychological, infectious and immunological disorders were taken into consideration.
I Guideline Information

Guidelines program of the DGGG, OEGGG and SGGG

Information on the guidelines program is available at the end of the guideline.

Citation format

Recurrent miscarriage: diagnostic and therapeutic procedures.

Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtsh Frauenheilk 2018; 78: 364–381

Guideline documents

The complete long version, a short version, a PDF slideshow for PowerPoint presentations and a summary of the conflicts of interest of all the authors are available in German on the AWMF homepage under: http://www.awmf.org/leitlinien/detail/ll/015-050.html

Guideline authors

See ▶ Table 1.

Table 1

The following professional and scientific societies/working groups/organisations/associations have stated their interest in contributing to the compilation of the guideline text and participating in the consensus conference and nominated representatives to attend the consensus conference.

<table>
<thead>
<tr>
<th>Author/Mandate holder</th>
<th>Working group/professional societies/organisations/associations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead author and coordinating author:</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. Bettina Toth</td>
<td>Austrian Society of Gynecology and Obstetrics (Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])</td>
</tr>
<tr>
<td></td>
<td>German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. [DGGG])</td>
</tr>
<tr>
<td></td>
<td>German Society for Gynecologic Endocrinology and Reproductive Medicine (Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin [DGGEF])</td>
</tr>
<tr>
<td>Prof. Dr. Clemens Tempfer</td>
<td>German Society of Gynecology and Obstetrics (DGGG)</td>
</tr>
<tr>
<td>Other lead authors:</td>
<td></td>
</tr>
<tr>
<td>Prof. Dr. Wolfgang Würfel</td>
<td>German Society of Gynecology and Obstetrics (DGGG)</td>
</tr>
<tr>
<td></td>
<td>German Society for Gynecologic Endocrinology and Reproductive Medicine (DGGEF)</td>
</tr>
<tr>
<td>Prof. Dr. M. Bohlmann</td>
<td>German Society of Gynecology and Obstetrics (DGGG)</td>
</tr>
<tr>
<td></td>
<td>Working Group Immunology in the DGGG (Arbeitsgemeinschaft Immunologie in der DGGG [AGIM])</td>
</tr>
<tr>
<td>Prof. Dr. J. Zschocke</td>
<td>German Society of Human Genetics (Deutsche Gesellschaft für Humangenetik e.V. [GfH])</td>
</tr>
<tr>
<td>Prof. Dr. S. Rudnik-Schöneborn</td>
<td>German Society of Human Genetics (GfH)</td>
</tr>
<tr>
<td>Prof. Dr. E. Schleußer</td>
<td>German Society of Ultrasound in Medicine (Deutsche Gesellschaft für Ultraschall in der Medizin e.V. [DEGUM])</td>
</tr>
<tr>
<td>PD Dr. N. Rogenhofer</td>
<td>Working Group Immunology in the DGGG (AGIM)</td>
</tr>
<tr>
<td>Prof. Dr. T. Wischmann</td>
<td>German Society for Fertility Counselling (Deutsche Gesellschaft für Kinderwunschberatung [BKID])</td>
</tr>
<tr>
<td>Prof. Dr. M. von Wolff</td>
<td>Swiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])</td>
</tr>
<tr>
<td>Prof. Dr. K. Hancke</td>
<td>German Society of Reproductive Medicine (Deutsche Gesellschaft für Reproduktionsmedizin [DGRM])</td>
</tr>
<tr>
<td>PD Dr. S. von Otte</td>
<td>Professional Association of Gynecologists (Berufsverband der Frauenärzte [BVF])</td>
</tr>
</tbody>
</table>
Abbreviations
Ab antibodies
ANA antinuclear antibodies
aPL antiphospholipid
APS antiphospholipid syndrome
ASA acetylsalicylic acid
ASRM American Society for Reproductive Medicine
FVL factor V Leiden
G-CSF granulocyte colony-stimulating factor
GM-CSF granulocyte-macrophage colony-stimulating factor
GW week of gestation
HLA human leukocyte antigen
IVIG intravenous immunoglobulin
LBR live birth rate
LIT lymphocyte immunization therapy
LMWH low-molecular-weight heparin
NK natural killer
PCO polycystic ovaries
PGD preimplantation genetic diagnosis
RCOG Royal College of Obstetricians and Gynaecologists
RM recurrent miscarriage
PT prothrombin
SGA small for gestational age
s/p status post
TPO thyroid peroxidase
TSH thyroid-stimulating hormone
VTE venous thromboembolism

II Guideline Application

Purpose and objectives
The aim of this guideline is to standardize the diagnosis and treatment of couples with recurrent miscarriage (RM) based on the most current national and international literature.

Targeted areas of patient care
Outpatient and/or inpatient care.

Target user groups/target audience
The recommendations of the guideline are addressed to gynecologists and their colleagues working in medical fields such as human genetics, psychotherapy, laboratory medicine, hemostasis, internal and general medicine and other professional staff involved in the care of patients with RM. Targeted patient group: couples with RM

Adoption of the guideline and period of validity
The validity of this guideline was confirmed by the respective boards/representatives of the participating professional medical societies, working groups, organizations and associations, by the board of the DGGG, SGGG and OEGGG and the DGGG/OEGGG/SGGG Guideline Commission in January 2018 and thereby approved in its entirety. This guideline is valid from February 1, 2018 through to January 31, 2021. The above-mentioned period of validity is only an estimate. The guideline can be updated earlier if urgently required. Should the guideline continue to reflect the current level of scientific knowledge, then the guideline’s period of validity can be extended.

III Methodology

Basic principles
Because of the complex biological processes which occur in the context of RM and the heterogeneity of the studies published on this topic, there is widespread uncertainty about the optimal individual diagnosis and therapy of women with RM. An updated S2k-level guideline was therefore considered advisable to improve the quality of care. The guideline aims to provide information and advice for women with RM about appropriate diagnostic procedures and evidence-based treatment strategies. In addition, the recommendations of the guideline should serve as the basis for interdisciplinary decision-making.

This guideline is based on the S1 guideline “Recurrent Miscarriage: Diagnostic and Therapeutic Procedures” (AWMF 015/050), published in 2013, and the results of a recent literature search (as per September 2017). The relevant literature was assigned to the various chapters with the help of degree candidate Eva Preisl and Dr. Katharina Feil, both from the University Hospital for Gynecological Endocrinology and Reproductive Medicine, Innsbruck, Austria. A coherent draft version was compiled from the individual chapters, which was edited in a joint advance consensus. Statements and recommendations which took the form of unambiguous instructions were then extracted from the draft text. The revised text was subsequently circulated among all the member of the guideline commission. The members proposed changes to the text and voted on the final manuscript.

This guideline is classified as: S2k

Grading of recommendations
As no systematic search, selection, evaluation and synthesis of the evidence base was carried out, the guideline does not discuss levels of evidence. The recommendations are graded as follows (Table 2):

Table 2 Grading of recommendations according to the respective syntax.

<table>
<thead>
<tr>
<th>Description</th>
<th>Syntax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong recommendation, strongly binding</td>
<td>must</td>
</tr>
<tr>
<td>Recommendation, moderately binding</td>
<td>should</td>
</tr>
<tr>
<td>Open recommendation, not binding</td>
<td>may</td>
</tr>
</tbody>
</table>

Statements
Expert statements included in this guideline which are not recommendations for action but are simple statements of fact are referred to as “Statements”. It is not possible to provide a level of evidence for these statements.
Achieving consensus and level of consensus

An interdisciplinary group voted on the statements and recommendations at three consensus conferences. The statements and recommendations of the guideline were discussed at consensus conferences held on 20th April 2017, 6th June 2017 and 19th September 2017 in Munich. Following a moderated formal consensus process, the participants of the conferences jointly consented to the statements and recommendations. The consent protocol is available on request.

During the compilation of this guideline, special consideration was given to existing recommendations (the guideline was first compiled in 2006 and revised in 2008 and 2013), the recommendations of the European Society of Human Reproduction and Embryology (ESHRE 2017), the Royal College of Obstetricians and Gynecologists [1], the American College of Obstetricians and Gynecologists (ACOG 2002) [2] and the American Society for Reproductive Medicine (ASRM 2012) [3].

During structured consensus-based decision-making (S2k/S3 level), authorized participants present at a session vote on draft Statements and Recommendations. Discussions during sessions may lead to significant changes in the wording of Statements and Recommendations, etc. The extent of agreement, which depends on the number of participants, is determined at the end of the session (▶ Table 3).

Expert consensus

As the name implies, this refers to consensus decisions taken with regard to specific Recommendations/Statements without a previous systematic search of the literature (S2e) or when evidence is lacking (S2e/S3). The term “Expert Consensus” (EC) used here is synonymous with terms such as “Good Clinical Practice” (GCP) or “Clinical Consensus Point” (CPP) used in other guidelines. The level of recommendation is graded as previously described in the Chapter “Grading of recommendations” but only semantically (“must/must not” or “should/should not” or “may/may not”) and without using the symbols shown there.

IV Guideline

1 Introduction

Counselling and treating couples with RM is a diagnostic and therapeutic challenge as several possible causes for RM are known, but no risk factor for RM is identified in the majority of affected patients.

2 Incidence and Definition

Approximately 1–3% of all couples of reproductive age experience recurrent miscarriage [4]. A miscarriage is defined as the loss of a fetus at any time between conception and the 24th week of gestation (GW) or the loss of a fetus weighing < 500 g [5]. The World Health Organization (WHO) definition of recurrent spontaneous miscarriage is: “three and more consecutive miscarriages before the 20th GW” [5]. The American Society for Reproductive Medicine (ASRM) already defines the occurrence of two consecutive miscarriages as RM [3, 6]. This definition increases the incidence of RM to 5% of all couples of reproductive age [7]. This guideline takes the WHO definition (≥ 3 consecutive recurrent miscarriages) as the basis for its recommendations on diagnostic and therapeutic procedures.

If a woman has not previously given birth to a live infant, the loss of the fetus is referred to as primary RM; if the woman has had a previous live birth, the pregnancy loss is referred to as secondary RM [8]. Another classification, which refers to the course of the miscarriages, classifies miscarriages into repeated loss of embryonic pregnancy (sporadic loss) or loss of fetal pregnancy (detectable heart beat on sonography or histologically verifiable embryo) [3].

The risk of recurrent miscarriage varies significantly, depending on a number of different factors. In addition to maternal age, the number of previous miscarriages also affects the risk of recurrence. ▶ Table 4 presents the data from a retrospective registry study [9].

▶ Table 3 Classification of extent of agreement in consensus decision-making.

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Level of consensus</th>
<th>Extent of agreement in percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>+++</td>
<td>Strong consensus</td>
<td>&gt; 95% of participants agree</td>
</tr>
<tr>
<td>++</td>
<td>Consensus</td>
<td>&gt; 75–95% of participants agree</td>
</tr>
<tr>
<td>+</td>
<td>Majority agreement</td>
<td>&gt; 50–75% of participants agree</td>
</tr>
<tr>
<td>–</td>
<td>No consensus</td>
<td>&lt; 50% of participants agree</td>
</tr>
</tbody>
</table>

▶ Table 4 Probability of recurrent miscarriage depending on maternal age and the number of previous miscarriages, based on the study of Nybo-Andersen et al. [9].

<table>
<thead>
<tr>
<th>Previous miscarriages</th>
<th>Risk of recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>25–29 years</td>
</tr>
<tr>
<td>1 miscarriage</td>
<td>~ 15%</td>
</tr>
<tr>
<td>2 miscarriages</td>
<td>~ 22–24%</td>
</tr>
<tr>
<td>≥ 3 miscarriages</td>
<td>~ 40–42%</td>
</tr>
</tbody>
</table>
3 Diagnosis and Treatment of Relevant Risk Factors

3.1 Lifestyle and behavior

3.1.1 Stress

Some studies have indicated that higher stress levels during pregnancy might be associated with an increased risk of pregnancy loss. A case-control study of 45 patients with RM concluded that stress levels were higher in 40 control patients [10]. A study of 301 patients with RM (defined as \( \geq 3 \) miscarriages) compared to women wanting to children reported similar findings [11]. Because of the small number of cases, it is not possible, based on the currently available data, to conclude that stress increases the risk of miscarriage.

3.1.2 Coffee consumption

A few observational studies have reported a dose-dependent relationship between coffee intake and late loss of pregnancy [12]. A larger case-control study was also able to show that coffee consumption had an impact on early miscarriage [13]. Another retrospective case-control study demonstrated a significantly increased risk of RM following coffee consumption in the periconceptual period and in early pregnancy. It was not possible to show a linear association between the amount of coffee consumed and the risk of miscarriage.

3.1.3 Nicotine and alcohol consumption

There is a strong association between nicotine consumption and poor obstetric and neonatal outcomes such as ectopic pregnancy, stillbirth, placenta previa, premature birth, low birthweight and congenital malformation. Cessation of smoking should therefore be recommended to all pregnant women [15]. The impact of smoking and of cessation of smoking on the risk of RM is not clear. A retrospective study compared 326 patients with RM with 400 control patients who had had at least one live birth. The study showed that even passive smoking significantly increased the risk of RM [16]. Another study came to the conclusion that maternal nicotine, alcohol or coffee consumption was not associated with a higher probability of RM [17].

A prospective study, which evaluated the impact of paternal smoking on the risk of miscarriage, investigated 526 couples and was able to show that women who were heavy smokers (> 20 cigarettes per day) had a higher risk of early miscarriage. Heavy smoking (more than 20 cigarettes per day) had a significantly greater impact than moderate smoking (< 20 cigarettes per day) [18]. There are currently no studies on the impact of smoking cessation on the chances of giving birth to a live infant for couples with RM.

3.2 Genetic factors

3.2.1 Chromosomal anomalies

Embryonic/fetal chromosomal abnormalities are the most common cause of spontaneous miscarriage [19,20]. The earlier the miscarriage occurs, the more likely that an embryonic/fetal chromosomal anomaly was present [21]. The risk of embryonic/fetal trisomy resulting from chromosomal aberrations increases with higher maternal age. The most common cause of miscarriage is trisomy 16, followed by trisomy 22. Triplet loss was detected in approximately 15% of cytogenetically abnormal fetuses. Monosomy X is responsible for approximately 20% of miscarriages which occur in the first trimester of pregnancy. No association with maternal age has been found for monosomy X, polyplody or structural chromosomal disorders [22]. A balanced chromosomal abnormality in one of the partners was confirmed in around 4–5% of couples who had 2 or more miscarriages [23]. In around 1% of pregnancies, an unbalanced set of chromosomes was detected during prenatal diagnostic procedures or after the birth [24,25].

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-2.E1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Level of consensus ++</td>
</tr>
</tbody>
</table>

Cytogenetic analysis must be done if a woman experiences recurrent miscarriages. This can be done either by chromosome analysis of both partners prior to conception or using tissue samples from the miscarried fetus.

It is not possible to carry out standard chromosomal analysis in around 18% of miscarried fetuses, and array analysis cannot be done in around 5% of miscarried fetuses [26]. Overall, molecular cytogenetic analysis only detected additional chromosomal disorders in around 5% of cases, and the routine use of array analysis to identify the cause of miscarriage is therefore not useful at present [26].

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-2.E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Level of consensus +++</td>
</tr>
</tbody>
</table>

Both partners must undergo cytogenetic testing if a structural chromosomal disorder is detected in the tissue of the miscarried fetus. The couple must be informed of the findings during genetic counselling carried out by a specialist for human genetics or a physician with the relevant qualifications in accordance with national legal regulations.

<table>
<thead>
<tr>
<th>Consensus-based Statement 3-2.S1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Level of consensus ++</td>
</tr>
</tbody>
</table>

If a balanced chromosomal aberration is detected in one of the parents, the risk of miscarriage or of giving birth to an infant with a chromosomal disorder increases, depending on the chromosomes involved. This will affect antenatal diagnostic procedures in any further pregnancies.

3.2.2 Monogenetic disease

X-linked dominant disorders that are lethal in males have an increased risk of miscarriage. But autosomal dominant and recessive disorders with severe malformations can also result in increased intrauterine mortality. In these cases, examination of the fetus should include genetic and pathological testing, particularly if the disorder was not identified prenatally.
3.2.3 Results of association studies
Numerous studies suggest possible maternal, paternal or fetal genetic effects, but these appear to have very little impact on the risk of miscarriage [27].

3.2.5 Therapeutic options
It is not possible to treat the causes of chromosomal disorders. Previous studies have not shown that PGD after IVF results in an increased rate of live births in women with RM compared to spontaneous pregnancies, not even for couples who are genetically at risk because one partner has a balanced chromosomal aberration. Neither the ESHRE and RCOG guidelines nor the ASRM Statement recommend preimplantation genetic diagnosis for couples with RM.

3.3 Anatomical factors
3.3.1 Diagnosis of anatomical factors
3.3.1.1 Congenital malformations
Hysteroscopic examinations of patients who had 2, 3 and ≥ 4 consecutive miscarriages found no difference in the prevalence of congenital (uterine malformations) or acquired (adhesions, polyps, submucosal fibroids) intrauterine pathologies [28]. The increased probability of miscarriage in women with septate uterus is well known, but the cause of this association is unknown [29]. It is not clear whether there is an association between RM and other uterine malformations such as arcuate uterus or bicornuate uterus. Ludwin et al. [30] reported significantly better diagnostic results when using sonohysterography (SHG) to diagnose congenital uterine malformations compared with hysterosalpingography (HSG) or hysteroscopy. But it is difficult to evaluate statements comparing diagnostic methods, because even when hysteroscopy videos were presented to experienced international observers, interobserver agreement was found to be poor [31].

When diagnosing uterine malformations, the decision whether to use hysteroscopy – possibly in combination with laparoscopy or 3D sonography – must be made on an individual basis [32]. 3D sonography is recommended for the diagnostic workup of uterine malformations in high-risk populations and MRI and endoscopic examinations are recommended for diagnostic problems or suspected complex malformations [33].

3.3.1.2 Acquired malformations
Although the study populations consisted only of women undergoing IVF, a meta-analysis of 19 observational studies showed a higher but not statistically significant rate of miscarriages in women with intramural fibroids and no submucosal involvement (relative risk [RR] 1.24; 95% CI: 0.99 – 1.57) [34]. In an evaluation of retrospective and prospective data of patients with RM, the incidence of submucosal fibroids was 2.6% (25/966) [35]. These study data suggest an association between submucosal fibroids and the occurrence of miscarriage, but the quality of the data is poor. A Cochrane analysis which only included a few studies showed no significant reduction in the risk of miscarriage after uterine fibroids had been resected (intramural: OR 0.89, 95% CI: 0.14 – 5.48; submucosal: OR 0.63, 95% CI: 0.09 – 4.40) [36].

It is not clear whether – as with submucosal fibroids – intracavitary polyps also increase the risk of miscarriage.

3.3.2 Treatment for anatomical factors
Hysteroscopic septum dissection is recommended for women with RM and septate uterus [37]. A meta-analysis carried out in 2017 showed that no randomized studies on the therapeutic effect of septum dissection have been carried out to date [38]. But retrospective uncontrolled studies suggest that the surgical intervention is beneficial. Postoperative healing takes about 2 months [39], and there are no reasons to avoid pregnancy thereafter. Surgical intervention is not indicated for other uterine malformations such as bicornuate uterus, uterus didelphys and arcuate uterus [40 – 42].
Hysteroscopic adhesiolysis is the therapy of choice to treat intrauterine adhesions [43]. It is not clear whether or to what extent intrauterine adhesions affect the risk of miscarriage and whether adhesiolysis will reduce the risk of RM.

There are no randomized studies on the therapeutic benefits of fibroid resection in women with RM.

A meta-analysis showed that hysteroscopic resection of intrauterine polyps visible on ultrasound carried out before intrauterine insemination can increase clinical pregnancy rates [44]. The resection of persistent polyps can be considered if there is no other explanation for RM.

### 3.4 Microbiological factors

#### 3.4.1 Diagnostic workup of microbiological factors

Because the association between infections and RM is unclear, general screening for vaginal infections which goes beyond the routine screening carried out as part of prenatal care is not recommended. However, chronic endometritis, as evidenced by the finding of plasma cells in the endometrial biopsy, was detected in 7–67% of otherwise asymptomatic women with RM and in 30–66% of women with recurrent implantation failure [45 - 49]. Endometrial biopsy may be performed in women with RM to exclude chronic endometritis (supported by immunohistochemical staining for the plasma cell surface antigen CD138).

#### 3.4.2 Treatment for microbiological factors

Pregnant women suspected of having a vaginal infection should receive proper testing and treatment [50, 51]. Antibiotic therapy with doxycycline (e.g. 200 mg 1–0–0 for 14 days) is indicated for chronic endometritis; in the event of persistent endometritis as evidenced by the persistence of plasma cells, treatment can consist of ciprofloxacin with/without metronidazole [45].

### 3.5 Endocrine factors

#### 3.5.1 Diagnostic workup of endocrine factors

According to a retrospective analysis, manifest hyperthyroidism is associated with increased miscarriage rates [52]. This also applies to manifest hypothyroidism. It is still unclear, however, whether latent hypothyroidism (i.e. increases in TSH concentrations despite thyroid hormone concentrations within normal ranges) also increases the risk of miscarriage. A meta-analysis of two studies reported that the LBR was not lower for women with RM and TSH concentrations of > 2.5 mU/L [53]. Increased levels of thyroid hormone autoantibodies appear to be associated with higher rates of spontaneous miscarriage [54]. PCOS, hyperandrogenemia (which is often PCOS-related [55]), insulin resistance [56, 57] and diabetes [58] are all associated with a higher tendency tomiscarry. PCOS per se is not a predictive factor for miscarriage or RM [59], whereas obesity per se appears to increase the rate of miscarriages.

#### 3.5.2 Treatment for endocrine factors

An endocrine workup determining TSH levels is recommended in women with RM. If TSH levels are found to be abnormal, fT3, fT4 and thyroid hormone autoantibody concentrations must also be determined.

The BMI of women with RM should be determined. Women with a BMI ≥ 30 kg/m² may be investigated further to determine whether they have a metabolic syndrome.
3.5.2 Treatment for endocrine factors

It is important to diagnose and treat manifest hyperthyroidism or hypothyroidism. A meta-analysis of studies of IVF patients with increased levels of thyroid hormone autoantibodies (RM was no inclusion criterion) and pregnant women with higher levels of TPO antibodies showed that substitution of thyroid hormones decreased the rate of miscarriages [54]. No statement was made about the rate of live births. However, other studies such as the study by Negro et al. published in 2016 [60] were unable to demonstrate the effect. It is therefore possible that patients with RM and TPO autoantibodies benefit from the substitution of thyroid hormones in terms of a lower rate of miscarriages, but currently there is no data specifically on patients with RM.

A meta-analysis found that the administration of metformin had no effect on the risk of sporadic miscarriage [61], and the guideline can therefore not make any recommendation regarding the administration of metformin.

There are many medical reasons why women with a high BMI should lose weight (cf. the S3 guideline on “Gestational Diabetes”, AWMF guideline 057/008). A Danish cohort study [62] showed that the risk of miscarriage increases for women with a BMI ≥ 30 kg/m² (OR 1.23; 95% CI: 0.98–1.54).

3.6 Psychological factors

Evidence-based medicine has not been able to show that RM can be directly caused by psychological factors such as stress alone [10, 63, 64].

3.7 Immunological factors

3.7.1 Diagnosis of immunological factors

3.7.1.1 Alloimmune factors

Activation of the immune system (particularly of the Th1 response) results in unfavorable conditions for implantation and is associated with an increased probability of RM [51, 65–69]. It has not yet been clearly proven that an increase in the Th1/Th2 ratio or T4/T8 index leads to an increased risk of miscarriage [51, 66, 70–73]. Several studies have pointed to an increase in natural killer cells in peripheral blood (pNK cells) in patients with RM compared to healthy controls [74–77]. Recent studies have also pointed to a significant increase in uterine natural killer cells (uNK cells) in patients with idiopathic RM [78, 79].

3.7.1.2 Autoimmune factors

Although the data are not consistent, the majority of studies report increased ANA titer levels in women with RM [80–86]. Celiac disease is characterized by gluten sensitivity; its association with RM is still controversially discussed. Testing for immunoglobulin
A (IgA) antibodies against tissue transglutaminase can be done in women with a history of food sensitivity (food intolerances, irregular bowel motions) and RM, followed by biopsy of the small intestine if the findings are positive [87].

Testing for antiphospholipid syndrome using clinical and laboratory parameters is recommended in women with RM (Fig. 1). Non-specific antibodies against anionic phospholipids such as cardiolipins and β2 glycoproteins, also known as antiphospholipid antibodies (aPLAb) have been detected in some women with RM. However, according to the definition given in Fig. 1, antiphospholipid (aPL) syndrome is only present if both clinical and laboratory criteria are fulfilled. Between 2% and 15% of women with RM suffer from aPL syndrome [88]. During the diagnostic workup, it is important to determine whether aPL antibody titer is still moderate to high at the 12-week follow-up after first determining the titer, i.e., whether it is in the > 99th percentile compared to remarkable controls [89].

A few studies have considered the possibility of so-called “non-criteria” aPL syndrome, particularly when manifestations (livedo reticularis, ulcers, renal microangiopathies, neurological disorders and cardiac manifestations) are present and the diagnostic criteria for classic aPL syndrome are not fulfilled or only in part (e.g., low aPLAb titer or s/p 2 miscarriages) [89].

**Clinical criteria**
- ≥ 1 venous or arterial thrombosis
- 1 or 2 unexplained miscarriages of morphologically normal fetuses after the 10th GW, ≥ 3 miscarriages before the 10th GW
- ≥ 1 late miscarriage or preterm birth before the 34th GW because of placental insufficiency or preeclampsia

**Laboratory criteria** (detected on 2 separate occasions at an interval of 12 weeks)
- Anti-cardiolipin antibodies (IgM, IgG) – moderate to high titer
- Anti-β2 glycoprotein 1 antibodies (IgM, IgG) – high titer
- Lupus anticoagulant

Testing for antiphospholipid syndrome based on clinical and laboratory parameters (Fig. 1) is recommended for women with RM.

**Consensus-based Recommendation 3-7.E22**

**Expert consensus**
Level of consensus +++

Testing for antiphospholipid syndrome based on clinical and laboratory parameters (Fig. 1) is recommended for women with RM.

**Consensus-based Recommendation 3-7.E23**

**Expert consensus**
Level of consensus +++

Interdisciplinary care must be offered to women with RM and an autoimmune disease already present prior to conception.

**Consensus-based Recommendation 3-7.E24**

**Expert consensus**
Level of consensus +

Testing for non-criteria antiphospholipid syndrome based on clinical and laboratory parameters should be done in women with RM, particularly if clinical manifestations are present (livedo reticularis, ulcers, renal microangiopathies, neurological disorders and cardiac manifestations).

3.7.2 Treatment for immunological factors

3.7.2.1 Glucocorticoids

The results of existing clinical studies which administered glucocorticoids to women with RM are inconsistent [90–93]. Treatment with glucocorticoids – particularly at higher doses – can induce side effects such as gestational diabetes, arterial hypertension, preterm birth, low birthweight (SGA) and disorders of neurological development in the infant [94–96]. This type of treatment should therefore be reserved for patients with pre-existing autoimmune diseases which require therapy with glucocorticoids even during pregnancy.

**Consensus-based Recommendation 3-7.E25**

**Expert consensus**
Level of consensus +

Glucocorticoids must not be administered outside clinical studies as prophylaxis to prevent miscarriage in women with RM but without pre-existing autoimmune disease.

3.7.2.2 Intravenous immunoglobulins

A few studies have pointed out that intravenous administration of immunoglobulins (IVIG) reduces the concentrations and activities of natural killer cells in peripheral blood and affects Th1-mediated immune response [97]. The studies were very heterogeneous and the majority were done in patients with idiopathic RM but without a specific immunological diagnostic workup prior to starting therapy. The data is inconsistent [97–100].

A recent meta-analysis which included 11 randomized studies of the type described above found no significantly higher LBR for the group of patients who received IVIG (RR 0.92; 95% CI: 0.75–1.12) compared to placebo or standard care [101]. A subgroup analysis showed a trend towards a benefit from IVIG in the cohort of patients with secondary RM compared to placebo (RR for no live births 0.77; 95% CI: 0.58–1.02; p = 0.06). There are currently no clearly defined indications for the administration of immunoglobulins, and they should therefore not be administered outside...
clinical studies. Side effects which can even include anaphylactic shock and the transmission of infectious pathogens are rare, but the incidence of occurrence is significantly higher in the verum group compared to controls.

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-7.E26</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Therapy with intravenous immunoglobulins to prevent miscarriage should not be given to women with RM outside clinical studies.</td>
</tr>
</tbody>
</table>

3.7.2.3 Lipid infusion

Current studies showed that soybean-oil-based lipid infusions reduced both NK cell activity and the formation of pro-inflammatory cytokines [102–106]. Small observational studies have shown that lipid infusions administered to women with RM or implantation failure and increased NK cell activity achieved the same live birth rates as treatment with IVIG [107–109]. A randomized placebo-controlled double-blind study carried out in Egypt investigated the impact of a single lipid infusion in a cohort von 296 women (with no tubal pathology and aged less than 40 years) undergoing IVF. The investigated women all had ≥ 3 idiopathic RM (consecutive clinical miscarriages after spontaneous conception or IVF/ICSI) and had elevated levels of peripheral blood NK cells (pNK cells > 12%) [110]. No significant difference in the rate of biochemical pregnancies was found between groups, but the rate of intact pregnancies > 12th GW and the rate of live births (37.5 vs. 22.4%, respectively; p = 0.005) was significantly higher in the group which had received a lipid infusion.

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-7.E27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Lipid infusion to prevent miscarriage should not be administered to women with RM outside clinical studies.</td>
</tr>
</tbody>
</table>

3.7.2.4 Allogeneic lymphocyte transfer (LIT)

The transfer of allogeneic lymphocytes (usually paternal lymphocytes, rarely donor lymphocytes, also known as lymphocyte immunization therapy) is a means of readying the maternal immune system to cope with the embryo’s foreign antigens (HLA). The data on the uses of this therapy in women with RM is inconsistent. Two recent meta-analyses pointed to higher LBR in patients with idiopathic RM who received LIT. However, these meta-analyses were strongly influenced by the weighting of an Asian study, published in 2013, which showed a positive effect [111–113]. Older studies found no benefit [114–116], meaning that, here too, further studies will be necessary. It should be noted that the transfusion of blood products can lead to complications (e.g., transmission of infections, formation of irregular autoantibodies, induction of autoimmune disorders).

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-7.E28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Allogeneic lymphocyte transfer to prevent miscarriage should not be carried out in women with RM outside clinical studies.</td>
</tr>
</tbody>
</table>

3.7.2.5 TNF-α receptor blockers

Subgroups of patients with RM have been reported to have increased TNF-α concentrations, abnormal TNF-α/IL-10 ratios or numbers of TNF-α-producing CD3+CD4+ lymphocytes, and these subgroups could benefit from the administration of TNF-α receptor blockers (e.g., adalimumab or infliximab) [100, 117]. However, only one retrospective study has looked at this issue to date. In addition to TNF-α receptor blockers, the study also used low-dose acetylsalicylic acid (ASA), low-molecular-weight heparin (LMWH) and immunoglobulins [100]. Well-known side effects ranged from skin reactions to infections and even rare adverse events such as drug-induced lupus [118]. There are also concerns regarding the possible induction of malignant disease by TNF-α blockers [119]. At present, the administration of TNF-α receptor blockers should be reserved for controlled clinical studies and for specific conditions (e.g., autoimmune diseases such as Crohn’s disease or chronic polyarthritis).

<table>
<thead>
<tr>
<th>Consensus-based Recommendation 3-7.E29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert consensus</td>
</tr>
<tr>
<td>Therapy with TNF-α receptor blockers should not be given to women with RM outside clinical studies.</td>
</tr>
</tbody>
</table>

3.7.2.6 Treatment for autoimmune factors

Because of the inconsistent data on the prevalence of antinuclear antibodies in women with RM, the current therapy strategies (ASA, glucocorticoids, low-molecular-weight heparin) are inconsistent and the guideline cannot offer any recommendations. There is currently only one retrospective study on the therapy of women with celiac disease and RM (n = 13) [120]. The women in the study benefitted from a gluten-free diet.

Therapy with low-dose acetylsalicylic acid and low-molecular-weight heparin is recommended for women with RM and antiphospholipid syndrome. Treatment with acetylsalicylic acid and heparin must be initiated as soon as the pregnancy test is positive. Aspirin administration must continue until GW 34 + 0, with heparin administration continuing for at least 6 weeks post partum. Numerous studies have shown that patients with RM and APS benefited from the administration of aspirin (50–100 mg/d) and low-molecular-weight heparin in prophylactic doses [121–125]. In contrast to the administration of LMWH and aspirin, other therapeutic approaches such as the administration of corticoids, immunoglobulins or aspirin alone did not result in any significant improvement in the LBR of patients with RM and APS [121].

Based on current studies, non-criteria aPL syndrome should be treated in exactly the same way, as a few studies have indicated a
potential benefit from the administration of LMWH in combination with ASA [126–130].

3.8 Coagulation

3.8.1 Diagnosis of congenital thrombophilic factors

Hereditary thrombophilic parameters are present in up to 15% of the Caucasian population [131]. In recent years, the assessment of maternal thrombophilia as an important risk factor for RM has significantly changed. Thrombophilia testing done only to prevent miscarriage is not recommended. International guidelines (ASRM, ACCP, RCOG) do not recommend routine testing for hereditary thrombophilia in women with RM [1, 3, 132–134]. The RCOG guideline considers testing for maternal hereditary thrombophilia to be only indicated in the context of scientific studies [133]. The ASRM recommendations propose thrombophilia testing for women with RM only if they have a medical or familial history of thromboembolic events [1, 3, 132–134].

Abnormalities in thrombophilic parameters may be an indication to treat pregnant women for medical reasons (prevention of thrombembolic events). Anticoagulation therapy to prevent maternal thromboembolism may be justified in pregnant women who have an increased risk of thromboembolic events (VTE) due to specific conditions (e.g., antithrombin deficiency, homozygous FVL mutation, combined heterozygous FVL and PT mutation, etc.) and in women with additional risk factors for VTE in pregnancy (immobilization, surgery, excessive weight gain, etc.) (ACOG 2013, AWMF 2015).

Consensus-based Recommendation 3.8.E30

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy with low-dose acetylsalicylic acid and low-molecular-weight heparin is recommended for women with RM and antiphospholipid syndrome. Treatment with acetylsalicylic acid and heparin must be initiated as soon as the pregnancy test is positive. Aspirin administration must continue until GW 34 + 0, with heparin administration continuing for at least 6 weeks post partum.</td>
<td></td>
</tr>
</tbody>
</table>

3.8.2 Treatment for women at risk of thrombophilic events

3.8.2.1 Heparin

Unfractionated and low-molecular-weight heparins differ with regard to their molecular weight, plasma protein binding, biological half-life and rate of side effects. In addition to their anticoagulation effect, they also have numerous effects at the molecular level of the embryo-maternal interface which are still not completely understood [135]. No heparins cross the placenta. The administration of low-molecular-weight heparin(s) during pregnancy is considered comparatively safe [136]. The administration of heparin in pregnancy is indicated, low-molecular-weight heparins should be used because of their superior side-effects profile and ease of administration [132]. The enthusiasm at the turn of the century about the impact of prophylactic heparin administration in women with RM has not been confirmed in either large prospective randomized studies [137–139] or in more recent meta-analyses [140].

The general maternal administration of heparin in subsequent pregnancies to women with RM without confirmed thrombophilia is not indicated because of the lack of proof of efficacy [141–143]. There is also no evidence for a beneficial effect of administering heparin prior to or during the conception period on the prevention of further miscarriages.

To what extent subgroups of patients (e.g., patients with confirmed hereditary thrombophilia) actually benefit from the administration of heparin in subsequent pregnancies requires further studies, such as the currently recruiting, multinational ALIFE2 trial [144]. At present, the general administration of heparin outside clinical studies for the indication “prevention of miscarriage” alone is not indicated, even in thrombophilic women with RM (in whom APS has not been confirmed) [132, 145].

Consensus-based Recommendation 3.8.E34

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with heparin with the sole purpose of preventing miscarriage is not recommended for women with RM. This also applies to women with hereditary thrombophilia.</td>
<td></td>
</tr>
</tbody>
</table>

Consensus-based Recommendation 3.7.E31

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy with low-dose acetylsalicylic acid and low-molecular-weight heparin is recommended for women with RM and non-criteria antiphospholipid syndrome. Treatment with acetylsalicylic acid and heparin must be initiated as soon as the pregnancy test is positive. Aspirin administration must continue until GW 34 + 0, with heparin administration continuing for at least 6 weeks post partum.</td>
<td></td>
</tr>
</tbody>
</table>

Consensus-based Recommendation 3.8.E32

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing for thrombophilia to prevent miscarriage is not recommended.</td>
<td></td>
</tr>
</tbody>
</table>
3.8.2.2 Acetylsalicylic acid (ASA)

The use of ASA in pregnancy to prevent miscarriage represents an off-label use. The administration of ASA in low doses starting in the 1st trimester of pregnancy reduces the risk of placenta-associated complications in late pregnancy [146], although it has not been possible to confirm any protective effect on the rate of miscarriages. The prospective randomized ALIFE trial in women with idiopathic RM reported that administration of aspirin prior to conception (80 mg/day) did not reduce the rate of miscarriages compared to placebo [138]. A systematic Cochrane meta-analysis found no benefit from the prophylactic administration of ASA in women with idiopathic RM (RR 0.94; 95% CI: 0.80–1.11) [147]. This also applies to the administration of aspirin prior to conception [148].

3.8.3 Monitoring during pregnancy – D dimers

Consensus-based Recommendation 3-8.E36

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus +++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylsalicylic acid therapy to prevent miscarriage is not recommended for women with RM.</td>
<td></td>
</tr>
</tbody>
</table>

3.9 Idiopathic RM

3.9.1 Diagnosis of idiopathic RM

Idiopathic RM is present if the criteria for a diagnosis of RM are met, and genetic, anatomical, endocrine, established immunological and hemostatic factors have been ruled out. The percentage of idiopathic RM in the total population of women with RM is high and amounts to 50–75% [2]. The percentage of live births for women with idiopathic RM who did not receive treatment is 35–85% [138, 149].

Consensus-based Recommendation 3-9.E37

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus +++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitoring of plasma coagulation markers (D dimers, prothrombin fragments, etc.) during pregnancy is not recommended in women with RM. Determination of these markers must not be used as an indication to initiate therapy to prevent miscarriage.</td>
<td></td>
</tr>
</tbody>
</table>

3.9.2 Therapy for idiopathic RM

A Cochrane meta-analysis of nine randomized studies which included 1228 women with idiopathic RM who had had at least two spontaneous miscarriages found no statistically significant effect of ASA with/without heparin on the LBR compared to placebo [147]. A randomized study of 364 women with idiopathic RM found that ASA administration had no impact on LBR compared to ASA and nadroparin or placebo [138]. Another meta-analysis of six randomized studies of 907 women with idiopathic RM also found no improvement in live birth rates following the administration of ASA and heparin [147].

Consensus-based Recommendation 3-9.E38

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus +++</th>
</tr>
</thead>
<tbody>
<tr>
<td>The term “idiopathic RM” is only used if the diagnostic workup described in this guideline is carried out and no cause of RM has been found.</td>
<td></td>
</tr>
</tbody>
</table>

A meta-analysis, published in 2017, of 10 randomized studies of 1586 women with idiopathic RM reported a positive effect following therapy with progestogens in the first trimester of pregnancy, both in terms of the rate of miscarriages (RR 0.72; 95% CI: 0.53–0.97) and the rate of live births (RR 1.07; 95% CI: 1.02–1.15). Synthetic progestogens, but not natural progesterone, were associated with a lower risk of recurrent miscarriage [150]. Synthetic progestogens can therefore be administered to women with idiopathic RM in the first trimester of pregnancy to prevent miscarriage. However, the optimal time for administration and the optimal dosage of the progestin are not yet clear.

In the PROMISE trial, a total of 836 women with idiopathic RM were randomized to receive either placebo or 400 mg micronized progesterone applied by vaginal suppository [151]. Treatment was initiated soon after positive urinary pregnancy test and continued up to and including the 12th week of gestation. The LBR was the same in both study arms (63 and 66%, respectively). However, a randomized study of 700 women with RM carried out in Egypt reported significantly higher live birth rates compared to placebo (91 vs. 77%) for 2 × 400 mg progesterone administered intravaginally, starting in the luteal phase [152].

Consensus-based Recommendation 3-9.E39

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus +++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with acetylsalicylic acid with or without additional heparin to prevent miscarriage is not recommended in women with idiopathic RM.</td>
<td></td>
</tr>
</tbody>
</table>

Consensus-based Recommendation 3-9.E40

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with natural micronized progesterone in the first trimester of pregnancy to prevent miscarriage is not recommended for women with idiopathic RM.</td>
<td></td>
</tr>
</tbody>
</table>

Consensus-based Recommendation 3-9.E41

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synthetic progestogens can be administered to women with idiopathic RM in the first trimester of pregnancy to prevent miscarriage.</td>
<td></td>
</tr>
</tbody>
</table>

Consensus-based Recommendation 3-9.E42

<table>
<thead>
<tr>
<th>Expert consensus</th>
<th>Level of consensus ++</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thromboprophylaxis for maternal indication should be given during pregnancy to women with RM and an increased risk of thromboembolic events.</td>
<td></td>
</tr>
</tbody>
</table>

Toth B et al. Recurrent Miscarriage: Diagnostic... Geburtsh Frauenheilk 2018; 78: 364–381
The effect of human chorionic gonadotropin (hCG) in doses of 5000–10 000 IE in the human first and second trimester of pregnancy was evaluated in five randomized studies of 596 women with RM, including women with idiopathic RM. A Cochrane meta-analysis of these five studies found that the administration of hCG led to a significant reduction in the frequency of miscarriage. However, this positive effect was no longer statistically significant when the analysis was done without the two methodologically weaker studies (OR 0.74; 95% CI: 0.44–1.23) [153]. The studies did not include data on LBR. There was no separate subgroup analysis for women with idiopathic RM. It is therefore currently not possible to recommend the administration of hCG to treat women with RM.

Scarpellini et al. carried out a randomized study in 68 women with RM who had previously had at least 4 consecutive spontaneous miscarriages. The women were randomized to receive either placebo or rh-G-CSF (1 µg/kg/day) starting on the 6th day after ovulation [154]. LBR for the active study arm was 83% (29/35) compared to 48% in the control group (16/33). In a retrospective cohort study Santjohanser et al. reported on 127 women with RM (for the purposes of that study, RM was defined as at least 2 spontaneous early miscarriages) who had IVF/ICSI [155]. Forty-nine of the women received either rh-G-CSF at a dose of 34 million units/week or 2 × 13 million units/week until the 12th week of gestation. The LBR was 32% higher following G-CSF administration compared to 13–14% for other patient groups. As a number of issues (e.g., the optimal dose) relating to G-CSF therapy are still unresolved, G-CSF should only be administered in the context of a clinical study.

### References


Bosteels J, Weyers S. Outpatient treatment for uterine polyps. BJM 2015; 350: h1469


Cicinelli E, Matteo M, Tinelli R et al. Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment. Reprod Sci 2014; 21: 640–647

McQueen DB, Bernardi LA, Stephensond MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril 2014; 101: 1026–1030


Anselmo J, Cao D, Karrison T et al. Fetal loss associated with excess thyroid hormone exposure. JAMA 2004; 292: 691–695


Christiansen OB. Evidence-based investigations and treatments of recurrent pregnancy loss. Curr Opin Obstet Gynecol 2006; 18: 304–312

Negro R, Schwartz A, Stagnaro-Green A. Impact of levothyroxine in miscarriage and preterm delivery rates in first trimester thyroid antibody-positive women with TSH less than 2.5 mIU/L. J Clin Endocrinol Metab 2016; 101: 3685–3690


Toth B et al. Recurrent Miscarriage: Diagnostic... Geburtsh Frauenheilk 2018; 78: 364–381


[65] Kwak-Kim JY, Chung-Bang HS, Ng SC et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod 2003; 18: 767–773


[100] Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 60: 8–16


Gris JC. LMWH have no place in recurrent pregnancy loss: debate against the motion. Thromb Res 2011; 127 (Suppl. 3): S110–S112

de Jong PG, Quenby S, Bloemenkamp KW et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia—study protocol for a randomized controlled trial. Trials 2015; 16: 208


de Jong PG, Kaandorp S, Di Nisio M et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage or with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; (7): CD004734


Guideline Program

Editors
Leading Professional Medical Associations

German Society of Gynecology and Obstetrics
(Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. [DGGG])
Head Office of DGGG and Professional Societies
Hausvogteiplatz 12, DE-10117 Berlin
info@dggg.de
http://www.dggg.de/

President of DGGG
Prof. Dr. Birgit Seelbach-Göbel
Universität Regensburg
Klinik für Geburtshilfe und Frauenheilkunde
St. Hedwig-Krankenhaus Barmherzige Brüder
Steinmetzstraße 1–3, DE-93049 Regensburg

DGGG Guidelines Representatives
Prof. Dr. med. Matthias W. Beckmann
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen

Prof. Dr. med. Erich-Franz Solomayer
Universitätsklinikum des Saarlandes
Geburtshilfe und Reproduktionsmedizin
Kirrberger Straße, Gebäude 9, DE-66421 Homburg

Guidelines Coordination
Dr. med. Paul Gaß, Christina Fuchs, Marion Gebhardt
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen
fk-dggg-leitlinien@uk-erlangen.de
http://www.dggg.de/leitlinienstellungnahmen

Austrian Society of Gynecology and Obstetrics
(Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])
Innrain 66A, AT-6020 Innsbruck
stephanie.leutgeb@oeggg.at
http://www.oeggg.at

President of OEGGG
Prof. Dr. med. Petra Kohlberger
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1180 Wien

OEGGG Guidelines Representatives
Prof. Dr. med. Karl Tamussino
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz
Auenbruggerplatz 14, AT-8036 Graz

Prof. Dr. med. Hanns Helmer
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1090 Wien

gynécologie suisse

Swiss Society of Gynecology and Obstetrics
(Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])
Gynécologie Suisse SGGG
Altenbergstraße 29, Postfach 6, CH-3000 Bern 8
sekretariat@sggg.ch
http://www.sggg.ch/

President of SGGG
Dr. med. David Ehlm
FMH für Geburtshilfe und Gynäkologie
Nägeligasse 13, CH-3011 Bern

SGGG Guidelines Representatives
Prof. Dr. med. Daniel Surbek
Universitätsklinik für Frauenheilkunde
Geburtshilfe und feto-maternale Medizin
Inselspital Bern
Effingerstraße 102, CH-3010 Bern

Prof. Dr. med. René Hornung
Kantonsspital St. Gallen, Frauenklinik
Rorschacher Straße 95, CH-9007 St. Gallen